Implications of PDE4 structure on inhibitor selectivity across PDE families

International Journal of Impotence Research

Volumn 16, Issue SUPPL. 1, 2004, Pages

  Ke, H ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

3 ,5 cyclic nucleotide phosphodiesterase; Binding sites; PDE4; Phosphodiesterase inhibitors; Protein conformation; Rolipram; Sildenafil

Indexed keywords

AMINO ACID; ASPARTIC ACID; CILOMILAST; CYCLIC AMP; CYCLIC GMP; DIVALENT CATION; HISTIDINE; MAGNESIUM ION; PHOSPHODIESTERASE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; ROLIPRAM; SILDENAFIL; ZARDAVERINE; ZINC ION;

ARTICLE; BINDING AFFINITY; BINDING SITE; CATALYSIS; CHEMICAL INTERACTION; CHEMICAL MODEL; CONSERVED CATALYTIC DOMAIN; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; ENZYME STRUCTURE; HYDROLYSIS; METAL BINDING; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; 3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; BINDING SITES; CATALYSIS; CRYSTALLIZATION; CYCLIC AMP; CYCLIC GMP; HUMANS; MAGNESIUM; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; SUBSTRATE SPECIFICITY; ZINC;

EID: 3342953638     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901211     Document Type: Article

References (16)

1. Xu RX et al. Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science 2000; 288: 1822-1825.
2. Huai Q et al. Three dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. Structure 2003; 11: 865-873.
3. Vallee BL, Auld DS. Zinc coordination, function, and structure of zinc enzymes and other proteins. Biochemistry 1990; 29: 5647-5659.
4. Wilcox DE. Binuclear metallohydrolases. Chem Rev 1996; 96: 2435-2458.
5. Hardman JG et al. The formation and metabolism of cyclic GMP. Ann NY Acad Sci 1971; 185: 27-35.
6. Percival MD, Yeh B, Falgueyret JP. Zinc dependent activation of cAMP-specific phosphodiesterase (PDE4A). Biochem Biophys Res Commun 1997; 241: 175-180.
7. Callahan SM, Cornell NW, Dunlap PV. Purification and properties of periplasmic 3′,5′-cyclic nucleotide phosphodiesterase. A novel zinc-containing enzyme from the marine symbiotic bacterium Vibrio fischeri. J Biol Chem 1995; 270: 17627-17632.
8. Omburo GA, Jacobitz S, Torphy TJ, Colman RW. Critical role of conserved histidine pairs HNXXH and HDXXH in recombinant human phosphodiesterase 4A. Cell Signal 1998; 10: 491-497.
9. Francis SH, Colbran JL, McAllister-Lucas LM, Corbin JD. Zinc interactions and conserved motifs of the cGMP-binding cGMP-specific phosphodiesterase suggest that it is a zinc hydrolase. J Biol Chem 1994; 269: 22477-22480.
10. Huai Q, Colicelli J, Ke H. The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis. Biochemistry 2003; 42: 13220-13226.
11. Huang Z, Ducharme Y, Macdonald D, Robichaud A. The next generation of PDE4 inhibitors. Curr Opin Chem Biol 2001; 5: 432-438.
12. Rotella DP. Phosphodiesterase 5 inhibitors: Current status and potential applications. Nat Rev Drug Discov 2002; 1: 674-682.
13. Dym O, Xenarios I, Ke H, Colicelli J. Molecular docking of competitive phosphodiesterase inhibitors. Mol Pharmacol 2002; 61: 20-25.
14. Lee ME, Markowitz J, Lee JO, Lee H. Crystal structure of phosphodiesterase 4D and inhibitor complex (1). FEBS Lett 2002; 530: 53-58.
15. Underwood DC et al. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. J Pharmacol Exp Ther 1994; 270: 250-259.
16. Saenz de Tejada I et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001; 13: 282-290.